Attached

August 19, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Incorporation of a Step-Down Subsidiary Company in Tashkent, Uzbekistan Ref: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Dear Sir/ Madam, We wish to inform you that Dr Lal PathLabs FZCO, Dubai, United Arab Emirates, Wholly Owned Subsidiary of the Company, has incorporated a Company in Tashkent, Uzbekistan named “Dr Lal PathLabs Indomed LLC” on August 19, 2026, and has agreed to subscribe 70% of its share capital. The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as amended from time to time is enclosed herewith as “Annexure – A”. Thanking You, Yours Faithfully, For Dr. Lal PathLabs Limited Vinay Gujral Company Secretary & Compliance Officer Encl.: As above Annexure-A DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023: S. No. Particulars Details 1 Name of the target entity, details in brief such Name of the incorporated entity: Dr Lal as size, turnover etc. PathLabs Indomed LLC Turnover, size: Not applicable, since it is a newly incorporated company. 2 Whether the acquisition would fall within Not Applicable, since this intimation is related party transaction(s) and whether the regarding the incorporation and agreed for promoter/ promoter group/ group companies subscription of the share capital of the Step- have any interest in the entity being acquired? Down Subsidiary of the Company. If yes, nature of interest and details thereof and whether the same is done at “arm’s length” 3 Industry to which the entity being acquired Diagnostic Services belongs 4 Objects and impact of acquisition (including To strengthen the Group’s presence in but not limited to, disclosure of reasons for Tashkent, Uzbekistan. acquisition of target entity, if its business is outside the main line of business of the listed entity) 5 Brief details of any governmental or Not Applicable regulatory approvals required for the acquisition 6 Indicative time period for completion of the Not Applicable acquisition 7 Consideration - whether cash consideration Cash Consideration or share swap or any other form and details of the same 8 Cost of acquisition and/or the price at which The subscription will be at face value the shares are acquired 9 Percentage of shareholding / control acquired 70% shareholding is being subscribed by Dr Lal and / or number of shares acquired PathLabs FZCO, Dubai, United Arab Emirates, Wholly Owned Subsidiary of the Company. 10 Brief background about the entity acquired in Dr Lal PathLabs Indomed LLC, Tashkent, terms of products/line of business acquired, Uzbekistan will be engaged in business of date of incorporation, history of last 3 years providing diagnostics services. turnover, country in which the acquired Date of Incorporation: August 19, 2026 entity has presence and any other significant information (in brief) Turnover: Not applicable (newly incorporated company). Country: Tashkent, Uzbekistan